| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Schmechtig, J Lees, A Perkins, A Altavilla, K J Craig, G R Dawson, J F William Deakin, C T Dourish, L H Evans, I Koychev, K Weaver, R Smallman, J Walters, L S Wilkinson, R Morris, S C R Williams, U Ettinge. The effects of ketamine and risperidone on eye movement control in healthy volunteers. Translational psychiatry. vol 3. 2014-06-05. PMID:24326395. |
these findings do not support the cognitive enhancing potential of risperidone on oculomotor biomarkers in this model system of schizophrenia and point towards the importance of developing alternative performance-enhancing compounds to optimise pharmacological treatment of schizophrenia. |
2014-06-05 |
2023-08-12 |
human |
| Kerry Taylor, Simon Elliot. An unusual case of risperidone instability in a fatality presenting an analytical and interpretative challenge. Drug testing and analysis. vol 5. issue 9-10. 2014-05-22. PMID:23868704. |
this paper describes the detection and characterization of unusual metabolite/breakdown products of the anti-psychotic drug risperidone in post-mortem blood and urine as part of a toxicological investigation into an unexpected death of a male suffering from paranoid schizophrenia prescribed risperidone and previously paroxetine. |
2014-05-22 |
2023-08-12 |
Not clear |
| Bruce J Kinon, Hong Liu-Seifert, Virginia L Stauffer, Jayanthi Jaco. Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clinical schizophrenia & related psychoses. vol 7. issue 3. 2014-05-12. PMID:23395836. |
the objective of this study was to determine the prevalence of low bmd in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment. |
2014-05-12 |
2023-08-12 |
Not clear |
| Antonios Paraschaki. Tackling negative symptoms of schizophrenia with memantine. Case reports in psychiatry. vol 2014. 2014-05-12. PMID:24818033. |
we present a case of a 52-year-old male patient suffering from chronic schizophrenia stabilized on risperidone long-acting injection (37,5 mg/2 weeks) and biperiden 4 mg/day. |
2014-05-12 |
2023-08-13 |
Not clear |
| Gordon G Liu, Shawn X Sun, Dale B Christensen, Zhongyun Zha. Choice of atypical antipsychotic therapy for patients with schizophrenia: An analysis of a medicaid population. Current therapeutic research, clinical and experimental. vol 66. issue 5. 2014-05-05. PMID:24790246. |
however, little is known about the influences on the choice between olanzapine and risperidone in patients with schizophrenia enrolled in medicaid. |
2014-05-05 |
2023-08-13 |
Not clear |
| Ofer Agid, Laura Schulze, Tamara Arenovich, Gautam Sajeev, Krysta McDonald, George Foussias, Gagan Fervaha, Gary Remingto. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 9. 2014-05-01. PMID:23706529. |
high doses yielded a 15.5% response (14.6% for risperidone vs. 16.7% for olanzapine).the present findings concur with other research indicating that response rate to the initial antipsychotic trial in first-episode schizophrenia is robust; thereafter it declines notably. |
2014-05-01 |
2023-08-12 |
human |
| Sha Liu, Yan-bo Yuan, Li-li Guan, Hui Wei, Zhang Cheng, Xue Han, Lei Yang, Cheng-cheng Pu, Fu-de Yang, Zheng Lu, Hong Deng, Jing-ping Zhao, Xin Y. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission. Chinese medical journal. vol 126. issue 14. 2014-04-30. PMID:23876895. |
mirna-365 and mirna-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission. |
2014-04-30 |
2023-08-12 |
human |
| Dieter Naber, Joseph Peuskens, Nadine Schwarzmann, Marc Goltz, Hagen Krüger, Martin Lambert, Josep Maria Har. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 10. 2014-04-24. PMID:23953270. |
subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine xr with risperidone (recover). |
2014-04-24 |
2023-08-12 |
Not clear |
| Dieter Naber, Joseph Peuskens, Nadine Schwarzmann, Marc Goltz, Hagen Krüger, Martin Lambert, Josep Maria Har. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 10. 2014-04-24. PMID:23953270. |
this randomised 12-month open study analysed the effectiveness of quetiapine xr (400-800 mg) versus risperidone (2-6 mg) on subjective well-being in schizophrenia (nct00600756). |
2014-04-24 |
2023-08-12 |
Not clear |
| Natasa Petronijevic, Jelena Sopta, Mirjana Doknic, Nevena Radonjic, Milan Petronijevic, Sandra Pekic, Nadja Maric, Miroslava Jasovic-Gasic, Vera Popovi. Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 46. 2014-04-22. PMID:23811489. |
chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. |
2014-04-22 |
2023-08-12 |
Not clear |
| Natasa Petronijevic, Jelena Sopta, Mirjana Doknic, Nevena Radonjic, Milan Petronijevic, Sandra Pekic, Nadja Maric, Miroslava Jasovic-Gasic, Vera Popovi. Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 46. 2014-04-22. PMID:23811489. |
most second generation antipsychotic drugs including risperidone are used in the treatment of schizophrenia. |
2014-04-22 |
2023-08-12 |
Not clear |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington, Robert R Bies, Takayuki Abe, Ariel Graff-Guerrero, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin. vol 39. issue 5. 2014-04-22. PMID:23821768. |
effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. |
2014-04-22 |
2023-08-12 |
Not clear |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington, Robert R Bies, Takayuki Abe, Ariel Graff-Guerrero, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin. vol 39. issue 5. 2014-04-22. PMID:23821768. |
in this open-label, 28-week, randomized controlled trial, stable patients with schizophrenia treated with risperidone or olanzapine were randomly assigned to the reduction group (dose reduced by 50% in 4 weeks and then maintained) or maintenance group (dose kept constant). |
2014-04-22 |
2023-08-12 |
Not clear |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington, Robert R Bies, Takayuki Abe, Ariel Graff-Guerrero, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin. vol 39. issue 5. 2014-04-22. PMID:23821768. |
this 6-month pilot study suggests that risperidone or olanzapine dose reduction of 50% can improve cognitive function for stable patients with schizophrenia. |
2014-04-22 |
2023-08-12 |
Not clear |
| R Gomeni, C Heidbreder, P J Fudala, A F Nasse. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. Journal of clinical pharmacology. vol 53. issue 10. 2014-04-21. PMID:23868656. |
rbp-7000 is a sustained-release (once-monthly injection for subcutaneous administration) formulation of risperidone using the atrigel® delivery system, developed for treatment of schizophrenia to address compliance issues associated with oral administration. |
2014-04-21 |
2023-08-12 |
Not clear |
| Eun Young Kim, Sung Man Chang, Joo Cheol Shim, Eun Jeong Joo, Jae Jin Kim, Yong Sik Kim, Yong Min Ah. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. Current medical research and opinion. vol 29. issue 10. 2014-04-07. PMID:23777311. |
long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. |
2014-04-07 |
2023-08-12 |
Not clear |
| Eun Young Kim, Sung Man Chang, Joo Cheol Shim, Eun Jeong Joo, Jae Jin Kim, Yong Sik Kim, Yong Min Ah. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. Current medical research and opinion. vol 29. issue 10. 2014-04-07. PMID:23777311. |
the current study compared the long-term effectiveness, safety, and tolerability of paliperidone extended-release (er) among patients with schizophrenia who had switched from risperidone (risperidone group) or other antipsychotic medications (non-risperidone group) due to lack of efficacy, intolerability, or non-adherence. |
2014-04-07 |
2023-08-12 |
Not clear |
| Thomas R Einarson, Hanna Pudas, Roman Zilbershtein, Rasmus Jensen, Colin Vicente, Charles Piwko, Michiel E H Hemel. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. Journal of medical economics. vol 16. issue 9. 2014-04-07. PMID:23844621. |
this study determined the cost-effectiveness of long-acting antipsychotic (lai) drugs paliperidone palmitate (pp-lai), olanzapine pamoate (olz-lai), and risperidone (ris-lai) for chronic schizophrenia. |
2014-04-07 |
2023-08-12 |
Not clear |
| Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun Nakamur. Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. Neuropsychiatric disease and treatment. vol 10. 2014-04-07. PMID:24707178. |
effect of blonanserin on cognitive and social function in acute phase japanese schizophrenia compared with risperidone. |
2014-04-07 |
2023-08-13 |
Not clear |
| Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun Nakamur. Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. Neuropsychiatric disease and treatment. vol 10. 2014-04-07. PMID:24707178. |
this study aims to determine the effectiveness of blonanserin (bns) on the cognitive and social functions of patients with schizophrenia compared with risperidone (ris) during acute-phase (8-week) treatment. |
2014-04-07 |
2023-08-13 |
Not clear |